首頁 > 市場調查報告書 > 醫療設備

麻醉

市場調查報告書

商品編碼

1624979

全球吸入麻醉市場按產品、最終用戶、應用、地區、範圍和預測劃分

Global Inhalation Anesthesia Market By Product (Desflurane, Isoflurane, Sevoflurane), By End-User (Hospital, Ambulatory Surgical Centers), By Application (Maintenance, Induction), By Geographic Scope and Forecast

出版日期: 2024年09月22日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

吸入麻醉的市場規模及預測

2024 年吸入麻醉市場規模價值為 18.2 億美元，預計到 2031 年將達到 27 億美元，2024 年至 2031 年的複合年增長率為 5.61%。在全球範圍內，吸入麻醉是指透過吸入輸送麻醉藥物的方法，在手術過程中促使可逆性的意識和感覺喪失。它廣泛用於手術中維持鎮靜，特別是對於需要長時間麻醉或精確麻醉管理的患者。最常用的藥物是七氟醚、異氟醚和地氟醚，透過面罩和機械呼吸器給藥。吸入麻醉通常應用於各種醫學專業的醫院和門診手術中心，包括一般外科、骨科和兒科。

輸送系統的進步和更安全、更有效的麻醉藥物的開發使得這項技術的未來充滿希望，推動其在醫療保健領域的持續應用。

吸入麻醉市場定義/概述

吸入麻醉是使用吸入麻醉藥物使您在醫療過程中失去意識並減輕疼痛。這些藥物通常使用面罩或呼吸管吸入並直接注射到患者的肺部。

此外，吸入麻醉廣泛應用於各種外科手術，包括一般外科手術、骨科手術、婦科手術和牙科手術。其用途包括住院和門診護理，為各個年齡層的患者提供安全有效的鎮靜。

全球吸入麻醉市場動態

主要市場驅動因子

手術數量增加

由於全球人口老化和慢性病的增加，外科手術的數量正在增加。根據世界衛生組織 (WHO) 的數據，每年進行超過 3.1 億例大型外科手術，推動了世界各地手術室對吸入麻醉的需求。

麻醉學的進展

七氟醚和地氟醚等更安全、更有效的吸入麻醉藥物的開發提高了麻醉的安全性。這些藥物可減少恢復時間和術後併發症，因此成為首選藥物。預計到 2027 年，全球對七氟醚的需求將以 4% 的複合年增長率成長。

門診手術增加

借助微創技術進行門診和當日手術的趨勢日益增長，推動了對短效麻醉解決方案的需求。在美國，到 2023 年，門診手術將佔所有外科手術的 60% 以上，這將促使吸入麻醉劑的需求激增。

增加對醫療基礎設施的投資

新興市場，尤其是亞太地區的新興市場，正大力投資醫療保健基礎設施。預計到 2023 年，光是中國就在醫療保健領域投資超過 700 億美元，這將推動對最新麻醉設備和解決方案（例如吸入麻醉）的需求。

主要問題

吸入麻醉劑成本高

七氟醚和地氟醚等現代麻醉劑的成本過高，尤其是對於中低收入國家的醫護人員而言，限制了它們的使用。

環境問題

眾所周知，吸入麻醉劑具有較高的全球暖化潛勢 (GWP)，並會促使氣候變遷。人們越來越擔心這些藥物對環境的影響，促使醫療保健產業探索更永續的替代品。

術後併發症的風險

雖然現代藥物通常是安全的，但有些患者會出現術後副作用，如噁心、嘔吐和呼吸問題。這可能會使醫療保健提供者猶豫是否使用吸入麻醉劑。

嚴格的監理要求

新型麻醉藥物的開發和批准在各國都面臨嚴格的監管，這減緩了市場成長並增加了將新產品推向市場的成本和時間。

主要趨勢：

轉向短效麻醉劑

人們越來越傾向於使用七氟醚和地氟醚等短效吸入麻醉劑，因為它們可以縮短恢復時間、減少術後併發症、提高患者吞吐量和手術效率。

配送系統的技術進步

麻醉輸送系統的創新，包括先進的蒸發器技術和自動化麻醉工作站，提高了吸入麻醉的精確度和安全性，從而實現了更有效、更可控的給藥。

門診量和門診手術量增加

門診和門診手術日益增長的趨勢推動了對促進快速恢復和最小副作用的吸入麻醉劑的需求，從而支持了當日手術數量的增加。

環保麻醉劑的出現

人們的注意力一直集中在開發具有低全球暖化潛勢 (GWP) 和對環境影響最小的環保吸入麻醉劑。

Inhalation Anesthesia Market size was valued at USD 1.82 Billion in 2024 and is projected to reach USD 2.7 Billion by 2031 , growing at a CAGR of 5.61% from 2024 to 2031 . Global inhalation anesthesia refers to a method of delivering anesthetic agents through inhalation, inducing a reversible loss of consciousness and sensation during surgical procedures. It is widely used in surgeries to maintain sedation, particularly for patients requiring long-term or precise anesthesia control. The primary agents used include sevoflurane, isoflurane, and desflurane, administered via masks or ventilators. Inhalation anesthesia is commonly applied in hospitals and ambulatory surgical centers across various medical fields, including general surgery, orthopedics, and pediatrics.

The future of this technique looks promising, with advancements in delivery systems and the development of safer, more efficient anesthetic agents driving its continued adoption in healthcare.

Inhalation Anesthesia Market: Definition/ Overview

Inhalation anesthesia is the use of anesthetic drugs through inhalation to induce unconsciousness and pain reduction during medical procedures. These drugs are usually inhaled using a mask or breathing tube and administered directly to the patient's lungs, where they are absorbed into the bloodstream and transported to the brain, causing loss of consciousness and pain.

Furthermore, inhalation anesthesia is widely utilized in a variety of surgical procedures, including general surgeries, orthopedic surgeries, gynecological treatments, and dental surgeries. Its applications include both inpatient and outpatient settings, providing safe and effective sedation to patients of all ages.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Inhalation Anesthesia Market Dynamics

The key market dynamics that are shaping the global inhalation anesthesia market include:

Key Market Drivers:

Rising Number of Surgical Procedures

: With an aging global population and increasing prevalence of chronic diseases, the number of surgeries is rising. According to the World Health Organization (WHO), over 310 million major surgeries are performed annually, driving the demand for inhalation anesthesia in operating rooms worldwide.

Advancements in Anesthetic Agents

: The development of safer and more efficient inhalation anesthetic agents, such as sevoflurane and desflurane, has enhanced the safety profile of anesthesia. These agents reduce recovery times and post-operative complications, making them preferred choices. The global demand for sevoflurane is expected to grow at a compound annual growth rate (CAGR) of 4% through 2027.

Increasing in Outpatient Surgeries

: The growing trend toward outpatient or same-day surgeries, supported by minimally invasive techniques, is driving demand for short-acting anesthetic solutions. In the U.S., outpatient surgeries accounted for over 60% of all surgical procedures in 2023, creating a surge in demand for inhalation anesthetics.

Rising Investments in Healthcare Infrastructure

: Emerging markets, particularly in Asia-Pacific, are investing heavily in healthcare infrastructure. China alone has invested over $70 billion in healthcare expansion in 2023, boosting the demand for modern anesthetic equipment and solutions like inhalation anesthesia.

Key Challenges:

High Cost of Inhalation Anesthetic Agents

: The cost of modern anesthetic agents, such as sevoflurane and desflurane, can be prohibitive for healthcare providers, particularly in low- and middle-income countries, limiting their adoption.

Environmental Concerns

: Inhalation anesthetics are known to have a high global warming potential (GWP), contributing to climate change. The environmental impact of these agents is becoming a growing concern, prompting the healthcare industry to seek more sustainable alternatives.

Risk of Post-Operative Complications

: Although modern agents are generally safe, some patients still experience post-operative side effects such as nausea, vomiting, and respiratory issues. This can deter healthcare providers from using inhalation anesthetics in certain cases.

Strict Regulatory Requirements

: The development and approval of new anesthetic agents face stringent regulations across different countries, slowing the market's growth and increasing the cost and time associated with bringing new products to market.

Key Trends:

Shift Towards Short-Acting Anesthetics

: There is an increasing preference for short-acting inhalation anesthetics such as sevoflurane and desflurane, which offer faster recovery times and reduced post-operative complications, enhancing patient throughput and surgical efficiency.

Technological Advancements in Delivery Systems

: Innovations in anesthesia delivery systems, including advanced vaporizer technologies and automated anesthesia workstations, are improving the precision and safety of inhalation anesthesia, leading to more effective and controlled administration.

Growth of Ambulatory and Outpatient Surgeries

: The rising trend of ambulatory and outpatient surgeries is driving the demand for inhalation anesthetics that facilitate quick recovery and minimal side effects, supporting the increased volume of same-day surgical procedures.

Emergence of Eco-Friendly Anesthetic Agents

: There is a growing focus on developing environmentally friendly inhalation anesthetics with lower global warming potential (GWP) and reduced environmental impact, driven by increasing awareness of sustainability and regulatory pressures.

Global Inhalation Anesthesia Market Regional Analysis

Here is a more detailed regional analysis of the global inhalation anesthesia market:

North America:

North America is the dominant region in the inhalation anesthesia market, driven by the high volume of surgical procedures and advanced healthcare infrastructure. The United States, in particular, leads in both market size and technological advancements. According to the Centers for Disease Control and Prevention (CDC), there are approximately 50 million surgical procedures performed annually in the U.S., creating a substantial demand for inhalation anesthesia. The region's focus on innovation and safety is supported by significant investments in research and development, contributing to its leading position in the global market.

In addition, North America benefits from a well-established network of healthcare facilities and high adoption rates of advanced anesthetic technologies. The U.S. and Canada are investing heavily in upgrading medical infrastructure, with the U.S. allocating over $20 billion for healthcare improvements in 2023 alone. This investment is enhancing the availability and quality of inhalation anesthesia, ensuring that North America remains at the forefront of the market.

Asia Pacific:

Asia Pacific is the fastest-growing region in the inhalation anesthesia market, fueled by rapid healthcare advancements and expanding medical infrastructure. Countries such as China and India are experiencing significant growth due to their large population bases and increasing healthcare investments. In 2023, China's healthcare sector received over $70 billion in investments, supporting the adoption of advanced anesthesia technologies. The rising number of surgeries and the push for modern healthcare facilities are driving the demand for inhalation anesthetics in the region.

Additionally, the expanding trend of medical tourism and the increasing focus on improving healthcare access in developing countries contribute to the growth of the inhalation anesthesia market in Asia Pacific. The region is seeing rapid advancements in both public and private healthcare sectors, enhancing the availability and use of modern anesthetic solutions.

Global Inhalation Anesthesia Market: Segmentation Analysis

The Global Inhalation Anesthesia Market is segmented on the basis of Product, End User, Application, and Geography.

Inhalation Anesthesia Market, By Product

Desflurane
Isoflurane
Sevoflurane

Based on Product, the Global Inhalation Anesthesia Market is segmented into Desflurane, Isoflurane, Sevoflurane. Sevoflurane is the dominant segment due to its favorable properties, including rapid onset, quick recovery, and minimal side effects, making it the preferred choice for various surgical procedures. Sevoflurane's ease of use and efficiency have established it as the leading anesthetic agent. Desflurane is the fastest-growing segment, driven by its ultra-fast onset and recovery times, which are increasingly sought after for outpatient and short-duration surgeries. The demand for desflurane is rising as healthcare providers aim for improved patient turnover and minimized anesthesia-related complications.

Inhalation Anesthesia Market, By End User

Hospital
Ambulatory Surgical Centers

Based on End User, the Global Inhalation Anesthesia Market is segmented into Hospital, Ambulatory Surgical Centers. Hospitals are the dominant segment due to their large volume of surgical procedures and advanced infrastructure, which necessitates the use of various anesthetic agents. However, Ambulatory surgical centers (ASCs) are the fastest-growing segment, driven by the increasing trend towards outpatient surgeries and minimally invasive procedures. ASCs are adopting inhalation anesthesia more rapidly due to its benefits in quick recovery and efficient patient throughput, reflecting a shift towards more cost-effective and patient-friendly surgical environments.

Inhalation Anesthesia Market, By Application

Maintenance
Induction

Based on Application, the Global Inhalation Anesthesia Market is segmented into Maintenance, Induction. Maintenance anesthesia is the dominant segment due to its critical role in sustaining anesthesia throughout lengthy surgical procedures, ensuring patient stability and comfort. Conversely, Induction anesthesia is the fastest-growing segment, driven by advancements in rapid-acting anesthetic agents that facilitate quicker onset and smoother transitions into the anesthetic state. The increasing preference for efficient and effective induction methods is reflecting the broader trend towards optimizing surgical workflows and enhancing patient experiences.

Inhalation Anesthesia Market, By Geography

North America
Europe
Asia Pacific
Rest of the World

Based on the Geography, the Global Inhalation Anesthesia Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America is the dominant region in the inhalation anesthesia market, driven by the high volume of surgical procedures and advanced healthcare infrastructure. The United States, in particular, leads in both market size and technological advancements. Asia Pacific is the fastest-growing region in the inhalation anesthesia market, fueled by rapid healthcare advancements and expanding medical infrastructure. Countries such as China and India are experiencing significant growth due to their large population bases and increasing healthcare investments.

Key Players

The "Global Inhalation Anesthesia Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market
AbbVie Inc., Baxter International Inc., Dechra Pharmaceuticals PLC, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd, Lunan Pharmaceutical Group Co. Ltd.
Our
market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
Global Inhalation Anesthesia Market: Recent Developments
In August 2024 Baxter International announced FDA approval for its latest anesthesia delivery system, designed to improve precision and safety in administering inhalation anesthesia. The system incorporates advanced monitoring features to enhance patient care during surgeries.
In July 2024 the European Medicines Agency approved Halofane, a new inhalation anesthetic agent by Halothane Pharma, noted for its reduced side effects and faster recovery times. This approval opens new markets across Europe and strengthens the company's product portfolio.
In June 2024 Drager launched a state-of-the-art vaporizer for inhalation anesthesia that offers precise dose adjustments and improved patient safety. This technology is expected to streamline anesthesia management and enhance surgical outcomes in hospitals globally.

1 INTRODUCTION OF GLOBAL INHALATION ANESTHESIA MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL INHALATION ANESTHESIA MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL INHALATION ANESTHESIA MARKET, BY PRODUCT

5.1 Overview
5.2 Desflurane
5.3 Isoflurane
5.4 Sevoflurane

6 GLOBAL INHALATION ANESTHESIA MARKET, BY APPLICATION

6.1 Overview
6.2 Maintenance
6.3 Induction

7 GLOBAL INHALATION ANESTHESIA MARKET, BY END-USER

7.1 Overview
7.2 Hospital
7.3 Ambulatory Surgical Centers

8 GLOBAL INHALATION ANESTHESIA MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East And Africa

9 GLOBAL INHALATION ANESTHESIA MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 AbbVie Inc.
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Baxter International Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Dechra Pharmaceuticals PLC
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Fresenius Kabi AG
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Hikma Pharmaceuticals PLC
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Jiangsu Hengrui Medicine Co. Ltd
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Lunan Pharmaceutical Group Co. Ltd
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Merck KGaA
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.7 Piramal Enterprises Limited
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Troikaa Pharmaceuticals Ltd
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments